NCT04714970

Brief Summary

The weight gain and metabolic dysfunction has been vital conditions for individuals with schizophrenia. rTMS is a promising novel intervention, which have strong potentials on moderating increased appetite and cognitive deficits in schizophrenia, as it has been proved for the treatment of depression. Therefore, the investigators designed this randomized controlled clinical trial to evaluate the efficacy and safety of rTMS, using iTBS pattern, on prevention and treatment for elevated appetite and cognitive deficiency in individual with schizophrenia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for not_applicable schizophrenia

Timeline
Completed

Started Apr 2021

Shorter than P25 for not_applicable schizophrenia

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 13, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 20, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

April 20, 2021

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

November 16, 2022

Status Verified

November 1, 2022

Enrollment Period

1.5 years

First QC Date

January 13, 2021

Last Update Submit

November 14, 2022

Conditions

Keywords

SchizophreniarTMSAppetiteCognitive Function

Outcome Measures

Primary Outcomes (3)

  • Change of Appetite

    Three-Factor Eating Questionnaire

    Change from Baseline to 6days and 36days

  • Change of MCCB

    The MATRICS™ Consensus Cognitive Battery

    Change from Baseline to 6days and 36days

  • Change of ERP

    Food picture ERP recorded by EEG

    Change from Baseline to 6days and 36days

Secondary Outcomes (7)

  • Change of fasting glucose

    Change from Baseline to 6days and 36days

  • Change of fasting insulin level

    Change from Baseline to 6days and 36days

  • Change of Triglyceride

    Change from Baseline to 6days and 36days

  • Change of Total Cholesterol

    Change from Baseline to 6days and 36days

  • Change of LDL

    Change from Baseline to 6days and 36days

  • +2 more secondary outcomes

Study Arms (2)

iTBS stimulation

EXPERIMENTAL

The participants randomized into experimental group will receive iTBS stimulation of dlPFC 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.

Device: iTBS

Sham stimulation

SHAM COMPARATOR

The participants randomized intoSham group will receive Sham stimulation, as the coil vertical to the brain surface, 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.

Device: Shame stimulation

Interventions

iTBSDEVICE

Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.

iTBS stimulation

TMS coil vertical to the brain surface, with same protocol as iTBS

Sham stimulation

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients with schizophrenia in accordance with DSM-5
  • Commorbid with significant weight gain after antipsychotics
  • Informed Consent

You may not qualify if:

  • Diagnosed with other mental disease in accordance with DSM-5
  • Comorbid with other severe physiological disease
  • Used antipsychotic, antidepressants, mood stabilizer, or other psychoactive substances before
  • Drug or alcohol abuse
  • Pregnant or lactating
  • Contraindication to rTMS

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Central South University

Changsha, Hunan, 410000, China

Location

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • Renrong Wu, Prof

    Central South University Psychiatry Department

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: 60 participants are randomized, through the predetermined random number list, into intervention group or sham stimulation group in equal.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 13, 2021

First Posted

January 20, 2021

Study Start

April 20, 2021

Primary Completion

November 1, 2022

Study Completion

December 1, 2022

Last Updated

November 16, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations